Latest & greatest articles for aripiprazole

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on aripiprazole or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on aripiprazole and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for aripiprazole

21. Abilify maintena (aripiprazole) Extended-Release Injectable Suspension

Abilify maintena (aripiprazole) Extended-Release Injectable Suspension Drug Approval Package: Brand Name (Generic Name) NDA # Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - ABILIFY MAINTENA (aripiprazole) Extended-Release Injectable Suspension Company: Otsuka Pharmaceutical Application No.: 202971 Approval Date: 02/28/2013 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF

2013 FDA - Drug Approval Package

22. Aripiprazole for treating moderate to severe manic episodes in adolescents with bipolar I disorder (TA292)

Aripiprazole for treating moderate to severe manic episodes in adolescents with bipolar I disorder (TA292) Overview | Aripiprazole for treating moderate to severe manic episodes in adolescents with bipolar I disorder | Guidance | NICE Aripiprazole for treating moderate to severe manic episodes in adolescents with bipolar I disorder Technology appraisal guidance [TA292] Published date: 24 July 2013 Share Guidance on aripiprazole for treating moderate to severe manic episodes in young people

2013 National Institute for Health and Clinical Excellence - Technology Appraisals

23. Aripiprazole - Schizophrenia and Related Psychotic Disorders

Aripiprazole - Schizophrenia and Related Psychotic Disorders Common Drug Review CEDAC Meeting – June 15, 2011 Notice of CEDAC Final Recommendation – July 18, 2011 Page 1 of 3 © 2011 CADTH CEDAC FINAL RECOMMENDATION ARIPIPRAZOLE – REQUEST FOR ADVICE (Abilify – Bristol-Myers Squibb Canada) Indication: Schizophrenia and Related Psychotic Disorders Recommendation: The Canadian Expert Drug Advisory Committee (CEDAC) recommends that aripiprazole be listed for the treatment of schizophrenia (...) and schizoaffective disorders in patients who have a contraindication to less expensive antipsychotic agents, or who failed a trial of less expensive antipsychotic agents because of intolerance or lack of response. Reason for the Recommendation: At the new submitted price, the average daily cost of treatment with aripiprazole is within the range of most of the costs of atypical agents currently reimbursed by participating drug plans. Background: Aripiprazole has a Health Canada indication for the treatment

2011 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

24. Aripiprazole effective for schizophrenia and well tolerated

Aripiprazole effective for schizophrenia and well tolerated PEARLS Practical Evidence About Real Life Situations PEARLS are succinct summaries of Cochrane Systematic Reviews for primary care practitioners. They Aripiprazole effective for schizophrenia and well tolerated Clinical question How effective is aripiprazole compared with other atypical antipsychotics for people with schizophrenia and schizophrenia-like psychoses? Bottom line On the basis of very limited data, aripiprazole (...) was not as effective (in terms of general mental state) as olanzapine but was as effective as risperidone. Aripiprazole was associated with less weight gain, cholesterol increase and sedation, and fewer prolactinrelated effects than olanzapine. Compared to risperidone, aripiprazole produced fewer dystonias, cardiac arrhythmias, and prolactin and cholesterol increases. However, tremor was more frequent in the aripiprazole group compared to those allocated risperidone. Caveat The overall premature discontinuation

2011 Cochrane PEARLS

25. Aripiprazole for the treatment of schizophrenia in people aged 15 to 17 years

Aripiprazole for the treatment of schizophrenia in people aged 15 to 17 years Overview | Aripiprazole for the treatment of schizophrenia in people aged 15 to 17 years | Guidance | NICE Aripiprazole for the treatment of schizophrenia in people aged 15 to 17 years Technology appraisal guidance [TA213] Published date: 26 January 2011 Share Guidance on aripiprazole for treating schizophrenia in young people aged 15 to 17. These recommendations are included in . Guidance development process

2011 National Institute for Health and Clinical Excellence - Technology Appraisals

26. Cost-effectiveness analysis of aripiprazole vs standard-of-care in the management of community-treated patients with schizophrenia: STAR study

Cost-effectiveness analysis of aripiprazole vs standard-of-care in the management of community-treated patients with schizophrenia: STAR study Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2011 NHS Economic Evaluation Database.

27. Metabolic effects and cost-effectiveness of aripiprazole versus olanzapine in schizophrenia and bipolar disorder Full Text available with Trip Pro

Metabolic effects and cost-effectiveness of aripiprazole versus olanzapine in schizophrenia and bipolar disorder Metabolic effects and cost-effectiveness of aripiprazole versus olanzapine in schizophrenia and bipolar disorder Metabolic effects and cost-effectiveness of aripiprazole versus olanzapine in schizophrenia and bipolar disorder Kasteng F, Eriksson J, Sennfalt K, Lindgren P Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS (...) EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to assess the cost-effectiveness of aripiprazole versus olanzapine for schizophrenia or bipolar disorder, focusing on the risk of developing treatment-related metabolic syndrome, leading to type 2 diabetes or coronary heart disease. The lower risk of metabolic syndrome

2011 NHS Economic Evaluation Database.

28. Aripiprazole (Abilify) - Schizophrenia in adolescents

Aripiprazole (Abilify) - Schizophrenia in adolescents Scottish Medicines Consortium Secretariat - Delta House 50 West Nile Street Glasgow G1 2NP Telephone 0141 225 6989 E-mail: rosie.murray@nhs.net Chairman Professor Kenneth R Paterson 1 aripiprazole 5, 10, 15, 30mg oral tablets, 10, 15mg orodisperible tablets and 1mg/1ml oral solution (Abilify®) (No: 630/10) Bristol-Myers Squibb Product Update 09 July 2010 The Scottish Medicines Consortium (SMC) has completed its assessment of the above (...) product and advises NHS Boards and Area Drug and Therapeutics Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows: ADVICE: following an abbreviated submission aripiprazole tablets, orodisperible tablets and oral solution (Abilify ® ) are accepted for restricted use within NHS Scotland. Indication under review: The treatment of schizophrenia in adolescents 15 years and older. SMC restriction: Restricted to initiation and management under the supervision of a child

2010 Scottish Medicines Consortium

29. Aripiprazole - Schizophrenia

Aripiprazole - Schizophrenia CEDAC FINAL RECOMMENDATION ARIPIPRAZOLE (Abilify – Bristol-Myers Squibb Canada) Indication: Schizophrenia and Related Psychotic Disorders Recommendation: The Canadian Expert Drug Advisory Committee (CEDAC) recommends that aripiprazole not be listed. Reasons for the Recommendation: Based on a CDR systematic review of 12 randomized controlled trials, efficacy outcomes, such as the Positive and Negative Syndrome Scale scores, were similar between aripiprazole and less (...) expensive antipsychotic agents. The average daily cost of treatment with aripiprazole is more than the cost of risperidone and most other antipsychotic agents. Of Note: 1. Based on a review of the clinical evidence, the Committee felt that a reduced price would increase the likelihood of a recommendation to “list” or “list with criteria.” 2. The Committee considered that antipsychotic agents are often used off-label to treat agitation and behavioural problems in elderly patients with dementia

2010 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

30. Review: Is aripiprazole as effective as risperidone in people with schizophrenia?

Review: Is aripiprazole as effective as risperidone in people with schizophrenia? Review: Is aripiprazole as effective as risperidone in people with schizophrenia? | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional (...) accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: Is aripiprazole as effective as risperidone in people with schizophrenia? Article Text Therapeutics Review: Is aripiprazole as effective as risperidone in people with schizophrenia? Statistics from Altmetric.com

2010 Evidence-Based Mental Health

31. The cost-effectiveness of aripiprazole as adjunctive therapy in major depressive disorder: Thai economic model

The cost-effectiveness of aripiprazole as adjunctive therapy in major depressive disorder: Thai economic model The cost-effectiveness of aripiprazole as adjunctive therapy in major depressive disorder: Thai economic model The cost-effectiveness of aripiprazole as adjunctive therapy in major depressive disorder: Thai economic model Leelahanaj T Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief (...) summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the cost-effectiveness of adding aripiprazole to conventional antidepressant treatment for patients with major depressive disorder who had not completely responded to at least one antidepressant. The author concluded that the addition of aripiprazole was not cost-effective in Thailand. The study was well presented

2010 NHS Economic Evaluation Database.

32. Refractory schizophrenia: adding aripiprazole to clozapine reduces negative but not overall symptoms

Refractory schizophrenia: adding aripiprazole to clozapine reduces negative but not overall symptoms Refractory schizophrenia: adding aripiprazole to clozapine reduces negative but not overall symptoms | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal (...) accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Refractory schizophrenia: adding aripiprazole to clozapine reduces negative but not overall symptoms Article Text Therapeutics Refractory schizophrenia: adding aripiprazole to clozapine

2009 Evidence-Based Mental Health

33. Switching to aripiprazole from olanzapine leads to weight loss in overweight people with schizophrenia or schizoaffective disorder

Switching to aripiprazole from olanzapine leads to weight loss in overweight people with schizophrenia or schizoaffective disorder Switching to aripiprazole from olanzapine leads to weight loss in overweight people with schizophrenia or schizoaffective disorder | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see (...) our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Switching to aripiprazole from olanzapine leads to weight loss in overweight people with schizophrenia or schizoaffective

2009 Evidence-Based Mental Health

34. Aripiprazole (Abilify®) tablets for the treatment of moderate to severe manic episodes in Bipolar I Disorder and for the prevention of a new manic episode in patients who experienced predominantly manic episodes and whose manic episodes responded to aripi

Aripiprazole (Abilify®) tablets for the treatment of moderate to severe manic episodes in Bipolar I Disorder and for the prevention of a new manic episode in patients who experienced predominantly manic episodes and whose manic episodes responded to aripi Aripiprazole (Abilify®) tablets for the treatment of moderate to severe manic episodes in Bipolar I Disorder and for the prevention of a new manic episode in patients who experienced predominantly manic episodes and whose manic episodes (...) responded to aripiprazole treatment Aripiprazole (Abilify®) tablets for the treatment of moderate to severe manic episodes in Bipolar I Disorder and for the prevention of a new manic episode in patients who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment All Wales Medicines Strategy Group (AWMSG) Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made

2009 Health Technology Assessment (HTA) Database.

35. UK cost-consequence analysis of aripiprazole in schizophrenia: diabetes and coronary heart disease risk projections (STAR study)

UK cost-consequence analysis of aripiprazole in schizophrenia: diabetes and coronary heart disease risk projections (STAR study) Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 NHS Economic Evaluation Database.

36. Treatment of psychotic symptoms in bipolar disorder with aripiprazole monotherapy: a meta-analysis

Treatment of psychotic symptoms in bipolar disorder with aripiprazole monotherapy: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 DARE.

37. Aripiprazole in major depression and mania: meta-analyses of randomized placebo-controlled trials

Aripiprazole in major depression and mania: meta-analyses of randomized placebo-controlled trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 DARE.

38. A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia (Abstract)

A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia Aripiprazole is a dopamine partial agonist approved for use in adults for short- and long-term treatment of schizophrenia and bipolar disorder. This study was designed to examine the acute efficacy, safety, and tolerability of aripiprazole for adolescents with schizophrenia.This was a 6-week multicenter, double-blind, randomized, placebo-controlled trial (...) . Subjects 13 to 17 years old with a DSM-IV diagnosis of schizophrenia and a Positive and Negative Syndrome Scale (PANSS) total score of 70 or more were randomly assigned (1:1:1 ratio) to placebo or 10 or 30 mg/day of aripiprazole. The primary endpoint was mean change from baseline to endpoint (last observation carried forward) in PANSS total score. Assessments of safety and tolerability included spontaneously reported adverse events, extrapyramidal symptom scores, serum prolactin concentration, body

2008 EvidenceUpdates Controlled trial quality: predicted high

39. A randomized, open-label comparison of 2 switching strategies to aripiprazole treatment in patients with schizophrenia: add-on, wait, and tapering of previous antipsychotics versus add-on and simultaneous tapering (Abstract)

A randomized, open-label comparison of 2 switching strategies to aripiprazole treatment in patients with schizophrenia: add-on, wait, and tapering of previous antipsychotics versus add-on and simultaneous tapering Although recent treatment guidelines for schizophrenia recommend that the prior antipsychotic agent should remain stable for at least 2 weeks when aripiprazole is introduced, there is no trial-based evidence to support this strategy. This study was designed to compare this strategy (...) with another conventional one in patients with schizophrenia. We conducted a randomized, 14-week, open-label trial to compare the following 2 switching strategies: (1) add-on of aripiprazole on a current regimen, wait for 4 weeks, and the tapering of prior antipsychotics and (2) add-on of aripiprazole and the simultaneous tapering of prior antipsychotics in patients with schizophrenia. Aripiprazole was initiated at 12 mg/d and then titrated between 12 and 30 mg. The previous antipsychotic medication

2008 EvidenceUpdates Controlled trial quality: uncertain

40. Haloperidol, olanzapine and risperidone reduce treatment failure compared to aripiprazole, quetiapine and ziprasidone in acute schizophrenia

Haloperidol, olanzapine and risperidone reduce treatment failure compared to aripiprazole, quetiapine and ziprasidone in acute schizophrenia Haloperidol, olanzapine and risperidone reduce treatment failure compared to aripiprazole, quetiapine and ziprasidone in acute schizophrenia | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use (...) cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Haloperidol, olanzapine and risperidone reduce treatment failure compared to aripiprazole, quetiapine

2008 Evidence-Based Mental Health